Five Prime Goes Public in Upsized Offering, Aerie Joins IPO Parade
This year’s flurry of initial public offering (IPO) activity continued Wednesday, as protein and antibody drug developer Five Prime Therapeutics Inc. priced an upsized offering to gross $64.5 million and ophthalmology firm Aerie Pharmaceuticals Inc. added its name to biotech’s IPO queue.
And more news is expected.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter